Pluri Inc. announced that its CDMO division (PluriCDMO?) has signed a manufacturing agreement with Remedy Cell Ltd, an innovative, biopharmaceutical company developing stem cell-derived, cell-free therapeutics for complex fibrotic conditions. PluriCDMO? will support Remedy Cell?s production team in the manufacturing of a clinical-grade Working Cell Bank (WCB) and GMP batches of Remedy Cell?s drug candidate RC-0315, derived from mesenchymal stem cells, towards the launch of their Phase Ib clinical trial for the treatment of Idiopathic Pulmonary Fibrosis (IPF), a lethal, complex, progressive interstitial lung disorder with a median survival of 3.8 years.
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
5.796 USD | +0.29% |
|
+5.01% | +25.03% |
Jul. 08 | Pluri Inc. Announces ?1 Million Proof of Concept Agreement to Enhance Global Sustainable Vegetable Supply | CI |
Jul. 02 | Pluri Appoints Liat Zalts as CFO | MT |
1st Jan change | Capi. | |
---|---|---|
+25.03% | 31.24M | |
+16.71% | 44.48B | |
+43.68% | 40.57B | |
-7.92% | 38.82B | |
+33.09% | 32.22B | |
-7.10% | 27.84B | |
+14.46% | 26.79B | |
+46.73% | 14.31B | |
+34.07% | 12.7B | |
-7.61% | 11.23B |
- Stock Market
- Equities
- PLUR Stock
- News Pluri Inc.
- Pluri Selected as Cdmo by Remedy Cell for Cell-Derived Cell-Free Drug Manufacturing